Trichostatin A Enhances the Response of Chemotherapeutic Agents in Inhibiting Pancreatic Cancer Cell Proliferation

Overview

Journal Virchows Arch

Specialties Cell Biology
Molecular Biology
Pathology

Date 2006 Mar 29

PMID 16568310

Citations 32

Authors

Paolo Piacentini

Massimo Donadelli

Chiara Costanzo

Patrick S Moore

Marta Palmieri

Aldo Scarpa

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is an aggressive neoplasia, and standard chemotherapies are by and large ineffective. The purpose of this work was to get a comprehensive preclinical study on the ability of anticancer drug combinations that best inhibit growth of pancreatic adenocarcinoma cells. We evaluated the in vitro growth inhibition of ten pancreatic cancer cell lines to gemcitabine and 5-fluorouracil, newer generation cytotoxic agents (oxaliplatin, irinotecan), targeted therapy (gefitinib) and a histone deacetylase (HDAC) inhibitor (trichostatin A). Cells were treated with the single drug alone and all pairwise drug association. Our results demonstrate that TSA can effectively increase the drug sensitivity of all the cell lines studied. The association of TSA and irinotecan determines an increase in growth inhibition on the highest percentage of cell lines (80%). Our findings may represent an experimental basis for potential clinical application of HDAC inhibitors, in particular in association with drugs used in cancer clinical treatment, supporting the idea that HDAC inhibitors could act as sensitizers for chemotherapy.

Citing Articles

Characterization of the effect of histone deacetylation inhibitors on CD8 T cells in the context of aging.

Toma G, Karapetian E, Massa C, Quandt D, Seliger B J Transl Med. 2022; 20(1):539.

PMID: 36419167 PMC: 9682763. DOI: 10.1186/s12967-022-03733-9.

Pharmacological Properties of Trichostatin A, Focusing on the Anticancer Potential: A Comprehensive Review.

Bouyahya A, El Omari N, Bakha M, Aanniz T, El Menyiy N, El Hachlafi N Pharmaceuticals (Basel). 2022; 15(10).

PMID: 36297347 PMC: 9612318. DOI: 10.3390/ph15101235.

Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy.

Laschanzky R, Humphrey L, Ma J, Smith L, Enke T, Shukla S Cancers (Basel). 2019; 11(9).

PMID: 31500290 PMC: 6770665. DOI: 10.3390/cancers11091327.

Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial-Mesenchymal Transition: Enhanced Efficacy when Combined with Gemcitabine.

Wei R, Penso N, Hackman R, Wang Y, Mackenzie G Nutrients. 2019; 11(8).

PMID: 31405071 PMC: 6722696. DOI: 10.3390/nu11081856.

The histone deacetylase class I, II inhibitor trichostatin A delays peripheral neurodegeneration.

Kim M, Park C, Jung J, Yeo S J Mol Histol. 2019; 50(2):167-178.

PMID: 30671879 DOI: 10.1007/s10735-019-09815-1.

References

Kelly W, Richon V, OConnor O, Curley T, MacGregor-Curtelli B, Tong W . Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003; 9(10 Pt 1):3578-88. View

Buchsbaum D, Bonner J, Grizzle W, Stackhouse M, Carpenter M, Hicklin D . Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys. 2002; 54(4):1180-93. DOI: 10.1016/s0360-3016(02)03788-4. View

Sawa H, Murakami H, Ohshima Y, Sugino T, Nakajyo T, Kisanuki T . Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol. 2002; 18(2):109-14. DOI: 10.1007/BF02479423. View

Patnaik A, Rowinsky E, Villalona M, Hammond L, Britten C, Siu L . A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clin Cancer Res. 2002; 8(7):2142-8. View

Moore P, Sipos B, Orlandini S, Sorio C, Real F, Lemoine N . Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch. 2002; 439(6):798-802. DOI: 10.1007/s004280100474. View

Kornmann M, Butzer U, Blatter J, Beger H, Link K . Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer. Eur J Surg Oncol. 2000; 26(6):583-7. DOI: 10.1053/ejso.2000.0951. View

Nervi C, Borello U, Fazi F, Buffa V, Pelicci P, Cossu G . Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. Cancer Res. 2001; 61(4):1247-9. View

Sandor V, Bakke S, Robey R, Kang M, Blagosklonny M, Bender J . Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002; 8(3):718-28. View

Cecconi D, Scarpa A, Donadelli M, Palmieri M, Hamdan M, Astner H . Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A. Electrophoresis. 2003; 24(11):1871-8. DOI: 10.1002/elps.200305430. View

10.

Haller D . New perspectives in the management of pancreas cancer. Semin Oncol. 2003; 30(4 Suppl 11):3-10. DOI: 10.1016/s0093-7754(03)00296-3. View

11.

Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M . Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res. 2004; 10(9):2936-43. DOI: 10.1158/1078-0432.ccr-03-0520. View

12.

Li D, Xie K, Wolff R, Abbruzzese J . Pancreatic cancer. Lancet. 2004; 363(9414):1049-57. DOI: 10.1016/S0140-6736(04)15841-8. View

13.

Marshall J, Rizvi N, Kauh J, Dahut W, Figuera M, Kang M . A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol. 2002; 2(6):325-32. DOI: 10.1046/j.1359-4117.2002.01039.x. View

14.

Vigushin D, Ali S, Pace P, Mirsaidi N, Ito K, Adcock I . Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001; 7(4):971-6. View

15.

Neoptolemos J, Cunningham D, Friess H, Bassi C, Stocken D, Tait D . Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol. 2003; 14(5):675-92. DOI: 10.1093/annonc/mdg207. View

16.

Monti P, Marchesi F, Reni M, Mercalli A, Sordi V, Zerbi A . A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch. 2004; 445(3):236-47. DOI: 10.1007/s00428-004-1053-x. View

17.

Paez J, Janne P, Lee J, Tracy S, Greulich H, Gabriel S . EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304(5676):1497-500. DOI: 10.1126/science.1099314. View

18.

Cassidy J, Misset J . Oxaliplatin-related side effects: characteristics and management. Semin Oncol. 2002; 29(5 Suppl 15):11-20. DOI: 10.1053/sonc.2002.35524. View

19.

Cascallo M, Calbo J, Gelpi J, Mazo A . Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer. Cancer Gene Ther. 2000; 7(4):545-56. DOI: 10.1038/sj.cgt.7700150. View

20.

Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K . Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991; 51(16):4187-91. View